Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02062632 · ClinicalTrials.gov registry record · Phase 2
Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy
A Phase 2 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT02062632: Clinical Trial Phase 2 study, sponsored by Mayo Clinic.
NCT02062632 is a Phase 2 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02062632, a Phase 2 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This randomized pilot clinical trial studies the effects of taking doxepin hydrochloride as compared to placebo (inactive drug) in treating esophageal pain in patients with cancer located in the chest area receiving radiation therapy to the thorax with or without chemotherapy. Doxepin hydrochloride is a tricyclic antidepressant drug which was recently shown to be helpful for mouth pain in patients receiving radiation therapy. Doxepin hydrochloride affects the surface of the esophagus, which may be helpful in reducing the pain caused by radiation therapy.
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Placebo
- OTHER Questionnaire Administration
- DRUG Doxepin Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2014-04-14 |
| Est. Completion | 2017-11-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02062632
The ClinicalTrials.gov registry entry for NCT02062632 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.
NCT02062632 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02062632 about?
NCT02062632 is a clinical study titled "Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy". This randomized pilot clinical trial studies the effects of taking doxepin hydrochloride as compared to placebo (inactive drug) in treating esophageal pain in patients with cancer located in the chest area receiving radiation therapy to the thorax with or without chemotherapy. Doxepin hydrochloride ...
What is the current status of trial NCT02062632?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2014-04-14. Estimated completion is 2017-11-06.
What interventions are being tested in trial NCT02062632?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Placebo (OTHER), Questionnaire Administration (OTHER), Doxepin Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT02062632?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.